pravastatin has been researched along with Innate Inflammatory Response in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.90) | 18.2507 |
| 2000's | 43 (62.32) | 29.6817 |
| 2010's | 23 (33.33) | 24.3611 |
| 2020's | 1 (1.45) | 2.80 |
| Authors | Studies |
|---|---|
| Andriessen, VC; Connell, MT; Flannagan, KS; Hill, MJ; Mumford, SL; Perkins, NJ; Plowden, TC; Radoc, JG; Schisterman, EF; Sjaarda, LA; Zolton, JR | 1 |
| Cseri, K; Csernoch, L; Szentesi, P | 1 |
| Colas, RA; Dalli, J; Souza, PR; Walker, ME | 1 |
| Anoopkumar-Dukie, S; Davey, AK; McFarland, AJ | 1 |
| Cannon, CP; Guo, J; Khan, N; Steen, DL; Umez-Eronini, AA | 1 |
| Chen, Y; Dai, M; Mei, X | 1 |
| Cho, O; Heo, TH; Kim, HS; Park, KY | 1 |
| de Craen, AJ; Ford, I; Jukema, JW; Lucke, J; Mooijaart, SP; Sattar, N; Stott, DJ; Trompet, S; Westendorp, RG | 1 |
| Gitirana, LB; Machado, MN; Magalhães, CB; Melo, AC; Porto, LC; Ribeiro, ML; Santos, JC; Valença, SS; Zin, WA | 1 |
| Cai, D; Chen, J; Chen, S; Hu, N; Kang, Y; Luo, L; Sun, J; Zhang, J | 1 |
| Angel-Zúñiga, JR; Cortés-Sanabria, L; Cueto-Manzano, AM; Martínez-Ramírez, HR; Ornelas-Carrillo, G; Rojas-Campos, E | 1 |
| Aktaş, SG; Atay, A; Çuhadar, S; Dursun, S; Köseoğlu, M | 1 |
| Badens, C; Bonello-Palot, N; Bourgeois, P; Dignat-George, F; Levy, N; Robert, S; Sabatier, F; Simoncini, S | 1 |
| Borba, CP; Cather, C; Cleary, SM; Copeland, PM; Fan, X; Freudenreich, O; Henderson, DC; Oppenheim, CE; Petruzzi, LJ; Stock, S; Vincenzi, B | 1 |
| Liu, J; Lu, P; Pang, X | 1 |
| Chu, L; He, L; Liang, Z; Mo, C; Qin, Y; Wang, X; Yang, F; Zhou, S | 1 |
| Hosomi, N; Kagimura, T; Kitagawa, K; Matsumoto, M; Minematsu, K; Nagai, Y; Nakamura, M; Ohtsuki, T; Origasa, H; Uchiyama, S | 1 |
| Caorsi, C; Munoz, C; Pineda, F | 1 |
| Haslinger-Löffler, B | 1 |
| Anantharamaiah, GM; Fogelman, AM; Hama, S; Hough, G; Lehrer, RI; Navab, M; Palgunachari, MN; Ruchala, P; Waring, AJ | 1 |
| Ozeç, I | 1 |
| Blauw, GJ; Buckley, BM; Cobbe, S; de Craen, AJ; Ford, I; Jukema, JW; Lowe, GD; Macfarlane, PW; Murphy, MB; Murray, HM; Packard, CJ; Sattar, N; Shepherd, J; Stott, DJ; Welsh, P; Westendorp, RG | 1 |
| Barber, MJ; Chasman, DI; Chatterjee, A; Hyde, CL; Krauss, RM; Li, X; Mangravite, LM; McCarty, CA; Nickerson, DA; Ridker, PM; Rieder, MJ; Rotter, JI; Smith, JD; Stephens, M; Wilke, RA; Williams, PT | 1 |
| Cairns, R; Cannon, CP; Michael Gibson, C; Nazer, B; Ray, KK | 1 |
| Banciu, M; Cabaj, M; Coimbra, M; de Smet, L; Fens, MH; Metselaar, JM; Schiffelers, RM; Storm, G | 1 |
| Ishibashi, T | 1 |
| Girardi, G | 1 |
| Basraon, SK; Costantine, MM; Hankins, GD; Longo, M; Makhlouf, M; Menon, R; Saade, GR | 1 |
| Baker, JV; Duprez, D; Grimm, R; Henry, K; Huppler Hullsiek, K; Neaton, JD; Prosser, R; Rhame, F; Tracy, RP | 1 |
| Anderson, JL; Zebrack, JS | 1 |
| Crisby, M; Janciauskiene, S; Lindgren, S; Sun, YX | 1 |
| Albert, MA; Glynn, RJ; Ridker, PM | 1 |
| Mascitelli, L; Pezzetta, F | 1 |
| Alexander, JS; Bharwani, S; Carter, P; Elrod, JW; Grisham, MB; Harada, H; Joh, T; Jordan, P; Manas, K; Sasaki, M; Warren, A; Wolcott, M | 1 |
| Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA | 1 |
| Fang, CH; Li, JJ | 1 |
| Egashira, K; Hirouchi, Y; Inoue, S; Kitajima, S; Kitamoto, S; Kohjimoto, Y; Nakano, K; Usui, M | 1 |
| Ford, I; Lowe, GD; McMahon, AD; O'Reilly, DS; Packard, CJ; Rumley, A | 1 |
| Egido, J; Tuñón, J | 1 |
| Colquhoun, DM; Heritier, SR; Kirby, AC; Nestel, PJ; Simes, RJ; Stewart, RA; Tonkin, AM; West, MJ; White, HD | 1 |
| Cha, JH; Kang, DH; Kang, SW; Kim, J; Kim, YS; Li, C; Lim, SW; Song, JC; Sun, BK; Yang, CW | 1 |
| Agrawal, A; Voleti, B | 1 |
| Cameron, JD; Hope, SA; Meredith, IT; Plunkett, JC; Worthley, SG | 1 |
| Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC | 1 |
| Dörge, H; Grabedünkel, J; Liakopoulos, OJ; Nagorsnik, U; Schmitto, JD; Schoendube, FA | 1 |
| Busser, E; de Kleijn, DP; de Vries, JP; Koekkoek, JA; Moll, FL; Pasterkamp, G; Schoneveld, A; van der Wal, AC; Velema, E; Verheijen, JH; Verhoeven, BA; Virmani, R | 1 |
| Nardi, H | 1 |
| Abolhassani, F; Ebrahimnejad, M; Jahanzad, I; Nouri, M; Pourabbasi, A | 1 |
| Clements, JD; Jamali, F | 1 |
| Gutkowski, K; Lubas, W | 1 |
| Bloigu, A; Erkkilä, L; Haasio, K; Jauhiainen, M; Laitinen, K; Leinonen, M; Saikku, P; Tiirola, T | 1 |
| Dagli, N; Karaca, I; Yavuzkir, M | 1 |
| Havekes, LM; Jukema, JW; Kleemann, R; Kooistra, T; Princen, HM; van der Hoorn, JW | 1 |
| Benson, R; Dever, GJ; Kennedy, S; Spickett, CM; Wainwright, CL | 1 |
| Chien, YH; Lee, WJ; Lee, WL; Liang, KW; Sheu, WH; Tang, YJ; Tsou, SS | 1 |
| Abe, M; Fukuhara, A; Kobayashi, H; Komuro, R; Matsuda, M; Miyata, Y; Nakayama, Y; Shimomura, I | 1 |
| Agardh, CD; Agardh, E; Gustavsson, C; Hagert, P | 1 |
| Ando, H; Fujimura, A; Kaneko, S; Saito, T; Sugimoto, K; Takamura, T; Tsuruoka, S; Yanagihara, H | 1 |
| Arita, S; Atiya, A; Joh, S; Kasraie, A; Mullen, Y; Ohtsuka, S; Saul, J; Une, S | 1 |
| Rosenson, RS; Tangney, CC | 1 |
| Ridker, PM | 1 |
| Avellone, G; Bono, M; De Simone, R; Di Garbo, V; Di Raimondo, D; Raneli, G | 1 |
| Caslake, MJ; Cooney, J; Ford, I; Krishna, M; Lowe, GD; Macphee, CH; McMahon, AD; O'Reilly, DS; Packard, CJ; Rumley, A; Suckling, KE; Wilkinson, FE | 1 |
| Arita, S; Maruyama, M; Mullen, Y; Nagai, T; Sakamoto, Y; Smith, CV | 1 |
| Crisby, M; Nilsson, J; Nordin-Fredriksson, G; Shah, PK; Yano, J; Zhu, J | 1 |
| Dorner, GT; Joukhadar, C; Klein, N; Prinz, M; Schmetterer, L; Schrolnberger, C; Vukovich, T; Wolzt, M | 1 |
| Davis, PM; Kiener, PA; Kowala, M; Murray, JL; Rankin, BM; Youssef, S | 1 |
| Azar, RR; Waters, DD | 1 |
| Guijarro, C | 1 |
4 review(s) available for pravastatin and Innate Inflammatory Response
| Article | Year |
|---|---|
[Anti-atherosclerotic and anti-inflammatory effects of statin on cardiovascular disease and their mechanisms].
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mevalonic Acid; Monomeric GTP-Binding Proteins; Plaque, Atherosclerotic; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Secondary Prevention | 2011 |
Role of inflammation in cardiovascular disease: how to use C-reactive protein in clinical practice.
Topics: Age Factors; Anticholesteremic Agents; Arteriosclerosis; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Humans; Inflammation; Pravastatin; Risk Factors; Sensitivity and Specificity | 2002 |
[C-reactive protein in cardiovascular diseases].
Topics: Algorithms; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Coronary Artery Disease; Humans; Inflammation; Inflammation Mediators; Pravastatin; Predictive Value of Tests; Risk Factors; Sensitivity and Specificity | 2006 |
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
Topics: Animals; Antithrombins; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Endothelium, Vascular; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Lovastatin; Muscle, Smooth, Vascular; Platelet Aggregation; Pravastatin; Simvastatin; Thromboplastin; Thrombosis | 1998 |
23 trial(s) available for pravastatin and Innate Inflammatory Response
| Article | Year |
|---|---|
Pilot randomized trial of short-term changes in inflammation and lipid levels during and after aspirin and pravastatin therapy.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Female; Humans; Inflammation; Lipids; Pilot Projects; Pravastatin; Treatment Outcome; Young Adult | 2019 |
The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Atorvastatin; Biomarkers; Colorimetry; Dose-Response Relationship, Drug; Fasting; Female; Follow-Up Studies; Hospitalization; Humans; Immunoturbidimetry; Inflammation; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Prognosis; Retrospective Studies | 2018 |
Circulating interleukin-6 concentration and cognitive decline in old age: the PROSPER study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cognition; Cognition Disorders; Confounding Factors, Epidemiologic; Cross-Sectional Studies; Executive Function; Female; Follow-Up Studies; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Interleukin-6; Ireland; Male; Netherlands; Neuropsychological Tests; Polymorphism, Single Nucleotide; Pravastatin; Promoter Regions, Genetic; Risk Assessment; Risk Factors; Scotland; Stroke | 2013 |
Anti-inflammatory interventions in end-stage kidney disease: a randomized, double-blinded, controlled and crossover clinical trial on the use of pravastatin in continuous ambulatory peritoneal dialysis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Humans; Inflammation; Kidney Failure, Chronic; Male; Mexico; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Placebos; Pravastatin; Treatment Outcome; Young Adult | 2013 |
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.
Topics: Adult; Anticholesteremic Agents; Cognition Disorders; Drug Synergism; Female; Humans; Inflammation; Lipid Metabolism; Male; Middle Aged; Pilot Projects; Pravastatin; Psychotic Disorders; Schizophrenia; Treatment Outcome | 2014 |
Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS.
Topics: Aged; Aged, 80 and over; Brain Ischemia; C-Reactive Protein; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Male; Middle Aged; Pravastatin; Recurrence; Risk; Stroke | 2017 |
Pravastatin immunomodulates IL-6 and C-reactive protein, but not IL-1 and TNF-alpha, in cardio-pulmonary bypass.
Topics: Aged; C-Reactive Protein; Cardiopulmonary Bypass; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1; Interleukin-6; Male; Middle Aged; Pravastatin; Risk Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2008 |
Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Female; Fibrinogen; Humans; Inflammation; Interleukin-6; Kaplan-Meier Estimate; Male; Myocardial Infarction; Pravastatin; Risk Factors; Stroke | 2009 |
Genome-wide association of lipid-lowering response to statins in combined study populations.
Topics: Adult; Aged; Atorvastatin; Bayes Theorem; Cholesterol; Female; Genome-Wide Association Study; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin | 2010 |
Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Observation; Pravastatin; Pyrroles; Treatment Outcome | 2010 |
Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Pressure; Cholesterol; Feasibility Studies; Female; Follow-Up Studies; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lisinopril; Male; Medication Adherence; Middle Aged; Placebos; Pravastatin; Treatment Outcome | 2012 |
Alcohol consumption and plasma concentration of C-reactive protein.
Topics: Alcohol Drinking; C-Reactive Protein; Cardiovascular Diseases; Cross-Sectional Studies; Ethanol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Risk Factors | 2003 |
[Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Disease; Drug Administration Schedule; Electrocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Platelet Aggregation; Pravastatin; Pyrroles; Time Factors | 2003 |
Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Case-Control Studies; Coronary Disease; Factor VII; Factor XIIa; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Incidence; Inflammation; Interleukin-6; Male; Middle Aged; Monocytes; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Predictive Value of Tests; Risk Factors; Scotland; Thrombophilia; Triglycerides | 2004 |
White blood cell count predicts reduction in coronary heart disease mortality with pravastatin.
Topics: Aged; Biomarkers; Coronary Disease; Female; Humans; Inflammation; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Pravastatin; Predictive Value of Tests; Prognosis; Stroke; Survival Rate | 2005 |
Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering.
Topics: Aged; Angina, Unstable; Biomarkers; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Logistic Models; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors | 2005 |
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors | 2006 |
[Clinical protocol. Pravastatin for the prevention of the destruction of the nutritional status of hemodialysis patients exhibiting chronic inflammation].
Topics: C-Reactive Protein; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Malnutrition; Placebos; Pravastatin; Renal Dialysis; Treatment Outcome | 2005 |
The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation.
Topics: Administration, Oral; Adult; Aged; Anticholesteremic Agents; Azetidines; Blood Glucose; C-Reactive Protein; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Insulin; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Pravastatin; Treatment Outcome; Triglycerides | 2007 |
Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia.
Topics: Anticholesteremic Agents; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Insulin Resistance; Male; Middle Aged; Pravastatin; Triglycerides | 2008 |
Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
Topics: Adipokines; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Cross-Over Studies; Female; Glucose Intolerance; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Pravastatin; Pyrroles | 2008 |
Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization.
Topics: Aged; Apolipoprotein B-100; Apolipoproteins B; Carotid Arteries; Carotid Artery Diseases; Cell Adhesion Molecules; Cell Death; Cholesterol; Collagen; Disease Progression; Endarterectomy, Carotid; Female; Humans; In Situ Nick-End Labeling; Inflammation; Lipid Metabolism; Lipoproteins; Male; Matrix Metalloproteinase 2; Metalloendopeptidases; Middle Aged; NF-kappa B; Pravastatin; Prospective Studies; Sweden; Tissue Inhibitor of Metalloproteinases; Treatment Outcome | 2001 |
Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Therapeutic Equivalency; Thrombophilia; Treatment Outcome | 2001 |
42 other study(ies) available for pravastatin and Innate Inflammatory Response
| Article | Year |
|---|---|
IL-6 production of C2C12 cells is enhanced in the presence of macrophages and pravastatin.
Topics: Humans; Inflammation; Interleukin-6; Macrophages; Muscle, Skeletal; Pravastatin | 2021 |
13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis.
Topics: Animals; Anticholesteremic Agents; Arthritis; Atorvastatin; Docosahexaenoic Acids; Inflammation; Leukocytes; Male; Mice; Mice, Inbred C57BL; Pravastatin | 2017 |
Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells.
Topics: Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Cell Proliferation; Chronic Disease; Dinoprostone; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Interleukin-1beta; Lipids; Lipopolysaccharides; Microglia; Monocytes; Nitric Oxide; Pravastatin; Quinolines; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; THP-1 Cells; Tumor Necrosis Factor-alpha | 2017 |
Pravastatin sodium attenuated TREM-1-mediated inflammation in human peripheral blood mononuclear cells.
Topics: Cells, Cultured; Cytokines; Humans; Inflammation; Leukocytes, Mononuclear; Lipopolysaccharides; NF-kappa B; Pravastatin; Triggering Receptor Expressed on Myeloid Cells-1 | 2019 |
A Comparison of the Anti-Inflammatory Effects of Four Combined Statin and Antiplatelet Therapies on Tumor Necrosis Factor-Mediated Acute Inflammation in vivo.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Cilostazol; Clopidogrel; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipopolysaccharides; Male; Mice; Platelet Aggregation Inhibitors; Pravastatin; Rosuvastatin Calcium; Treatment Outcome; Tumor Necrosis Factor-alpha | 2019 |
Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury.
Topics: Animals; Atorvastatin; Biomarkers; Endotoxins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lung Injury; Male; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin | 2013 |
[Protective effects of pravastatin against P38MAPK signaling pathway-mediated inflammatory toxicity in islet micro-endothelial cells].
Topics: Animals; Apoptosis; Endothelial Cells; Endothelium, Vascular; Inflammation; Islets of Langerhans; MAP Kinase Signaling System; Mice; Nitric Oxide Synthase Type II; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pravastatin | 2013 |
The anti-inflammatory and antioxidant effects of pravastatin and nebivolol in rat aorta.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Aorta; Ceruloplasmin; Cholesterol; Coronary Artery Disease; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Nebivolol; NG-Nitroarginine Methyl Ester; Pravastatin; Rats; Rats, Wistar; Triglycerides; Uric Acid | 2014 |
Prelamin A accumulation in endothelial cells induces premature senescence and functional impairment.
Topics: Atazanavir Sulfate; Cell Adhesion; Cell Proliferation; Cells, Cultured; Cellular Senescence; Diphosphonates; Endothelial Cells; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Inflammation; Intercellular Adhesion Molecule-1; Lamin Type A; Microscopy, Fluorescence; Monocytes; Neovascularization, Pathologic; Nuclear Proteins; Oligopeptides; Pravastatin; Progeria; Protein Precursors; Pyridines; Umbilical Cord; Umbilical Veins; Zoledronic Acid | 2014 |
Pravastatin inhibits fibrinogen- and FDP-induced inflammatory response via reducing the production of IL-6, TNF-α and iNOS in vascular smooth muscle cells.
Topics: Animals; Atherosclerosis; Cell Line; Dose-Response Relationship, Drug; Fibrin Fibrinogen Degradation Products; Fibrinogen; Inflammation; Interleukin-6; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitric Oxide Synthase Type II; Pravastatin; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 2015 |
The effect of pravastatin on carotid artery thrombosis in rats under the stimulus of C-reactive protein.
Topics: Animals; Anticholesteremic Agents; C-Reactive Protein; Carotid Artery Diseases; Inflammation; Platelet Aggregation; Pravastatin; Rats; Thrombosis | 2016 |
Multiple effects of HMG-CoA reductase inhibitors (statins) besides their lipid-lowering function.
Topics: Animals; Cholesterol; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Interleukin-6; Kidney; Mice; Pravastatin; Reperfusion Injury | 2008 |
A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins E; Atherosclerosis; Biological Availability; Female; Humans; Inflammation; Lipoproteins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Mimicry; Niclosamide; Peptides; Pravastatin; Protein Structure, Secondary | 2009 |
Re: Statin-induced bone morphogenetic protein (BMP) 2 expression during bone regeneration: an immunohistochemical study.
Topics: Animals; Bone Morphogenetic Protein 2; Bone Regeneration; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pravastatin; Rabbits; Simvastatin | 2009 |
Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation.
Topics: Angiogenic Proteins; Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokines; Genes, MHC Class I; Humans; Inflammation; Lipid Metabolism; Liposomes; Male; Mice; Mice, Inbred C57BL; Neoplasms; Pravastatin | 2010 |
Role of tissue factor in pregnancy complications: crosstalk between coagulation and inflammation.
Topics: Abortion, Habitual; Animals; Anticholesteremic Agents; Blood Coagulation; Complement Activation; Complement System Proteins; Female; Humans; Inflammation; Mice; Pravastatin; Pre-Eclampsia; Pregnancy; Thromboplastin | 2011 |
Can statins reduce the inflammatory response associated with preterm birth in an animal model?
Topics: Animals; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Pravastatin; Pregnancy; Premature Birth; Simvastatin | 2012 |
Pravastatin inhibits pro-inflammatory effects of Alzheimer's peptide Abeta(1-42) in glioma cell culture in vitro.
Topics: Amyloid beta-Peptides; Brain Neoplasms; Cell Nucleus; Colorimetry; Cytokines; Electrophoresis, Polyacrylamide Gel; Electrophoretic Mobility Shift Assay; Free Radicals; Glioma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipid Peroxidation; Matrix Metalloproteinase 9; Metalloendopeptidases; Peptide Fragments; Pravastatin; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tumor Cells, Cultured | 2003 |
The PROSPER trial.
Topics: Aged; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Humans; Inflammation; Patient Selection; Pravastatin; Predictive Value of Tests; Primary Prevention; Risk Factors | 2003 |
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis.
Topics: Animals; Cell Adhesion Molecules; Cell Membrane Permeability; Cholesterol; Colitis; Dextran Sulfate; Disease Models, Animal; Enzyme Inhibitors; Epithelial Cells; Gene Expression; Hydroxymethylglutaryl CoA Reductases; Immunoglobulins; Immunohistochemistry; Inflammation; Mice; Mice, Inbred C57BL; Mice, Knockout; Mucoproteins; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pravastatin; RNA, Messenger | 2003 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aorta, Abdominal; Aortic Diseases; Arteriosclerosis; Catheterization; Chemokine CCL2; Chemotaxis; Cholesterol; Cytokines; Diet, Atherogenic; DNA, Complementary; Drug Evaluation, Preclinical; Genetic Therapy; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iliac Artery; Immunoglobulin G; Immunoglobulin M; Inflammation; Macaca fascicularis; Male; Peptidyl-Dipeptidase A; Phenotype; Pravastatin; Random Allocation; Renin; Transfection | 2004 |
[Endothelial dysfunction, inflammation and statins: new evidences].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Circulation; Endothelium, Vascular; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Interleukin-6; Pravastatin; Pyrroles; Rabbits; Time Factors | 2004 |
Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy.
Topics: Animals; C-Reactive Protein; Cyclosporine; Disease Models, Animal; Fibrosis; Inflammation; Kidney; Kidney Diseases; Losartan; Male; Pravastatin; Rats; Rats, Sprague-Dawley | 2005 |
Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist.
Topics: Anticholesteremic Agents; C-Reactive Protein; Down-Regulation; Gene Expression Regulation; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1; Interleukin-6; Nitric Oxide; Pravastatin; RNA, Messenger; Simvastatin; STAT3 Transcription Factor; Tumor Cells, Cultured | 2006 |
Effects of preoperative statin therapy on cytokines after cardiac surgery.
Topics: Aged; Anti-Inflammatory Agents; Atorvastatin; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Heart Arrest, Induced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-10; Interleukin-6; Male; Postoperative Complications; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2006 |
Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cytokines; Dose-Response Relationship, Drug; Endarterectomy, Carotid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Macrophages; Peptide Hydrolases; Phenotype; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Pravastatin prevents ischemia-reperfusion injury in rat sciatic nerve.
Topics: Animals; Axons; Cytoprotection; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Neuroprotective Agents; Oxidative Stress; Peripheral Nerves; Pravastatin; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Sciatic Neuropathy; Time Factors; Treatment Outcome; Wallerian Degeneration | 2006 |
Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Biological Availability; C-Reactive Protein; Disease Models, Animal; Down-Regulation; Drug Interactions; Electrocardiography; Heart Conduction System; Heart Rate; Inflammation; Interferon-gamma; Interleukin-10; Male; Mycobacterium; Nitrites; Pravastatin; Propranolol; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Time Factors | 2007 |
Effect of pravastatin treatment on Chlamydia pneumoniae infection, inflammation and serum lipids in NIH/S mice.
Topics: Animals; Chlamydophila Infections; Chlamydophila pneumoniae; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Mice; Mice, Inbred Strains; Pravastatin | 2007 |
Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoprotein E3; Atherosclerosis; Blood Pressure; Collagen; Diet, Atherogenic; Drug Synergism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation; Lipids; Macrophages; Mice; Mice, Transgenic; Monocytes; Muscle, Smooth, Vascular; Pravastatin; Recombinant Proteins; Serum Amyloid A Protein; T-Lymphocytes; Tetrazoles | 2007 |
Phospholipid chlorohydrin induces leukocyte adhesion to ApoE-/- mouse arteries via upregulation of P-selectin.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Arteries; Atherosclerosis; Cell Adhesion; Chlorohydrins; Hypochlorous Acid; Inflammation; Intercellular Adhesion Molecule-1; Leukocytes; Lipoproteins, LDL; Mice; Mice, Knockout; Nitrates; P-Selectin; Phosphatidylcholines; Phospholipids; Pravastatin; Reactive Oxygen Species; Up-Regulation | 2008 |
Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interferon Regulatory Factor-3; Interferon-beta; Interleukin-6; Macrophages; Male; Mice; Mice, Obese; Myeloid Differentiation Factor 88; Obesity; Pravastatin; Quinolines; Signal Transduction; Toll-Like Receptor 4 | 2008 |
Inflammatory markers in nondiabetic and diabetic rat retinas exposed to ischemia followed by reperfusion.
Topics: Animals; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Docosahexaenoic Acids; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Pravastatin; Rats; Rats, Wistar; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2008 |
Islet protective effect of pravastatin from nonspecific inflammation in mouse pancreatic islet isografts.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Inflammation; Islets of Langerhans Transplantation; Mice; Mice, Inbred BALB C; Niacinamide; Pravastatin; Transplantation, Isogeneic | 1996 |
Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation.
Topics: C-Reactive Protein; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic | 2000 |
Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response.
Topics: Blood Coagulation Factors; Blood Glucose; Case-Control Studies; Cholesterol; Coronary Artery Disease; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors | 2000 |
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol; Coronary Disease; Fibrinogen; Humans; Hypercholesterolemia; Inflammation; Leukocyte Count; Logistic Models; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2; Pravastatin; Risk Factors; Triglycerides | 2000 |
Islet graft primary nonfunction and its prevention.
Topics: Animals; Animals, Newborn; Antioxidants; Blood Glucose; Chromans; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Graft Survival; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Islets of Langerhans Transplantation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pravastatin; Subrenal Capsule Assay; Transplantation, Homologous; Transplantation, Isogeneic | 2000 |
Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Cell Line; Chemokine CCL2; Cholesterol; Cytokines; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Inflammation; Interleukin-1; Interleukin-8; Leukocytes; Male; Mice; Mice, Inbred C57BL; Monocytes; Pravastatin; Reactive Oxygen Species; Tumor Necrosis Factor-alpha | 2001 |
PRINCE's prospects: statins, inflammation, and coronary risk.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Humans; Inflammation; Pravastatin | 2001 |
High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pravastatin; Predictive Value of Tests; Risk Assessment; Sensitivity and Specificity | 2001 |